Quanterix Corporation

Quanterix Corporation is a for-profit life sciences company headquartered in Billerica, Massachusetts, that specializes in ultra-sensitive digital biomarker detection technology. The company is best known for its proprietary Simoa (single molecule array) platform, which enables the detection of proteins and biomarkers at extremely low concentrations from small sample volumes, making it particularly valuable for advanced biomedical research and diagnostic development. As a federal contractor and grant recipient, Quanterix provides sophisticated laboratory equipment, assay kits, reagents, maintenance services, and custom assay development to support the research initiatives of multiple federal agencies. The company has maintained continuous registration in the System for Award Management since May 2007 and has established itself as a reliable supplier of specialized biomarker detection capabilities across the federal research enterprise.

Through its federal contract awards, Quanterix Corporation has demonstrated a consistent pattern of supplying critical biomarker detection equipment, consumables, and support services to federal agencies without set-aside designations, reflecting the specialized and unique technological capabilities required for its products. The company has received numerous purchase orders from the National Institutes of Health components, including the National Institute of Child Health and Human Development (NICHD), National Institute on Aging (NIA), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Allergy and Infectious Diseases (NIAID), and National Cancer Institute (NCI), with contracts ranging from approximately $10,000 to over $250,000 in individual award values. Contract deliverables have included Simoa HD-X and SR-X analyzer systems, specialized assay kits (including neurology, p-tau, and HIV-related biomarker assays), reagents, buffers, maintenance and warranty packages, technical support services, and custom assay development. The Department of Veterans Affairs has been a major contracting partner, awarding multiple purchase orders through various Veterans Integrated Service Networks for research services utilizing single molecule array assays, analyzer maintenance packages, and assay kits, with individual awards ranging from $10,000 to over $250,000. Additional federal agencies contracting with Quanterix include the Centers for Disease Control and Prevention (CDC Pittsburgh), which awarded maintenance contracts for the Quanterix SP-X system; the Department of Agriculture's Agricultural Research Service, which contracted for preventive and emergency maintenance services; and the Department of Health and Human Services' general operations offices for custom assay development and equipment maintenance. All contract awards have been structured as firm fixed-price purchase orders with no small business set-asides, and Quanterix has served as the prime contractor on all awards, with work performed primarily at its Billerica, Massachusetts facility or at designated federal agency locations.

Quanterix Corporation's federal grant activity demonstrates its engagement in advanced research and development initiatives focused on diagnostic innovation. The company holds a significant cooperative agreement from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), valued at $18.2 million, for the development of a point-of-care device using single molecule array technology to measure viral antigens in nasal swabs, saliva, and blood samples. This collaborative project, which runs through August 2025, partners Quanterix with Boston Children's Hospital and the University of Toronto to create a sample-to-answer benchtop instrument that combines Simoa detection technology with digital microfluidics processing to enable immunoassays with the sensitivity and specificity comparable to nucleic acid amplification tests. The initial focus of the grant work involves developing assays for COVID-19 and influenza diagnosis, with optimization of assays for SARS-CoV-2 N-protein and development of multiplexed assays for influenza A and B antigens. This grant represents Quanterix's role as a prime awardee in a cutting-edge research initiative aimed at advancing point-of-care diagnostics while maintaining the analytical performance standards of central laboratory testing. The cooperative agreement structure underscores Quanterix's position as an innovation leader in biomarker detection technology and its capability to serve as a principal investigator and technology provider in complex, multi-institutional research partnerships.

Quanterix Corporation holds a single indefinite delivery contract (IDC) awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 4, with a ceiling value of $2,964,080 and an award date of July 15, 2021. This IDC authorizes the provision of research services utilizing single molecule array assays to support the VA-VHA's ongoing biomedical research programs, enabling the detection of proteins at subfemtomolar concentrations from small sample volumes. Multiple firm fixed-price delivery orders have been issued against this IDC vehicle, including a large delivery order valued at $2,836,490 awarded in July 2021 for services through May 2022, a delivery order valued at $243,958 (later noted as $223,158) awarded in July 2022 for work through July 2025, and a delivery order valued at $149,600 awarded in July 2023 for services extending through July 2024. The IDC represents the primary indefinite delivery mechanism through which the VA-VHA has structured its ongoing relationship with Quanterix for research services, rather than relying on individual purchase orders, demonstrating confidence in the company's capabilities and operational reliability. All work under the IDC has been performed in Billerica, Massachusetts, with Quanterix serving as the prime contractor, and the contract vehicle does not fall under any larger parent contract or government-wide acquisition contract vehicle.